NASDAQ: KRRO

Korro Bio, Inc.

Healthcare | Biotechnology

No licensed closing price on file for KRRO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Korro Bio, Inc. (NASDAQ: KRRO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 00:33 UTC.

What Korro Bio, Inc. does

The company is developing oligonucleotides, a relatively new class of drugs, for genetic diseases where clinical experience is limited. The company may pursue expedited development pathways such as FDA accelerated approval or the European PRIME scheme, though these designations do not change approval standards and provide no assurance of faster review or approval. Because oligonucleotide and RNA editing therapies are novel, regulatory agencies have limited experience with them and have not established definitive development guidelines, which may slow or complicate regulatory review.

Summarized from Korro Bio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-15

2026-09-15DirectorSale-31,888$450.3K
2026-09-15DirectorSale-1,750$24.5K
2026-09-15DirectorSale-8,450$118.2K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Lynx1 Capital Management LP1,538,296$20.27M0.0%
NEA Management Company, LLC1,297,893$17.11M0.0%
Venrock Adviser, LLC1,009,500$13.31M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-10-08Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-11-14Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-11-06AuditorChanges in registrant's certifying accountantRSMEstimatedSEC 8-K →

Company news

View all →

No qualifying company news in the archive. Full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for KRRO and 5,000+ tickers.

Create a free account — keep KRRO

For your agent

GET /api/data?ticker=KRRO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt